Nii Amankra Kwashie Tetteh new MD of Bayport Ghana

The Board of Directors of Bayport Savings and Loans Ltd (Bayport) have announced the appointment of Nii Amankra Kwashie Tetteh as Managing Director of the Company.

His appointment was approved by Bank of Ghana on the December 11, 2017. Nii Amankra Kwashie Tetteh also joins the Company’s board of Directors.

“I am confident Nii will lead us to more successes as we continue to build a Bigger and Better Bayport” says Mr. Kwame Pianim, chairman of Bayport’s board of directors.

Nii Amankra Kwashie Tetteh replaces Kofi Adu-Mensah who is leaving the company after 13 years of dedicated service.

He joins Bayport from Barclays Bank of Ghana Ltd, where he was Director, Retail & Business Banking.

Bayport new

Board chair, Mr Kwame Pianim (far right) introducing the new MD to management of Bayport

He started his banking career at Standard Chartered Bank in August of 2001.  In February 2006, following his passion for SME Banking, He joined Barclays Bank as a Business Development Manager.

Nii Amankra then joined the Barclays Retail Banking Business in 2009 and was confirmed as Head of Retail Distribution in 2010 a key member of the team that turned the Barclays Retail Business around, building it into Ghana’s leading Retail Banking Business.

In August of 2014, Nii Amankra joined the Regional Office of the Retail Banking Business for Barclays Africa Group Limited as Head for Branch Optimization covering Barclays Africa’s 12 Markets outside of South Africa.

Nii Amankra returned to Barclays Bank of Ghana Limited, in September of 2016 as Director, Retail & Business Banking a role he held until assuming the managing directorship of Bayport. Savings and Loans limited.

Nii Amankra is an Alumnus of China Europe International Business School, Shanghai, University of Leicester, UK, the University of Ghana, Legon and an old student of Mfantsipim School.

He is married and has three children.

Show More


  1. The expressed receptor ligand or the antibody target or the cellular immunotherapy target may be chosen from the following list of receptors ligands or targets including but not limited to; Proto oncogene tyrosine protein kinase ABL1, Citrullinated Antigen, ErbB2 HER2, CD16, WT 1, KRAS, glypican 3, CD3, CD20, CD226, CD155, CD123, HPV 16 E6, Melan A MART 1, TRAIL Bound to the DR4 Receptor, LMP, MTCR, ESO, NY ESO 1, gp100, 4SCAR GD2 CD56, Mesothelin CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN; DNA Synthesis Inhibitor; Histamine H1 Receptor HRH1 Antagonist; Prostaglandin G H Synthase 2 Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1 cialis with dapoxetine 2020 Mar; 77 6 1197 1207

  2. Adult Clinical Studies A double blind, placebo controlled, multicenter US clinical trial involving obese patients with type 2 diabetes mellitus whose hyperglycemia was not adequately controlled with dietary management alone baseline fasting plasma glucose FPG of approximately 240 mg dL was conducted viagra pictures before and after D RHEB, a small GTPase involved in mTORC1 regulation, is an example of a high modularity network containing many clusters of densely interconnected genes

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button